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Abstract 18 
Achondroplasia is a clinical condition defined by shorter stature and 19 
disproportionate limb length. Force production in able-bodied individuals (controls) 20 
is proportional to muscle size, but given the disproportionate nature of 21 
Achondroplasia, normalising to anatomical cross sectional area (ACSA) is 22 
inappropriate. The aim of this study was to assess specific force of the vastus 23 
lateralis (VL) in 10 adults with Achondroplasia (22 3 yrs) and 18 gender matched 24 
controls (22 2 yrs). Isometric torque (iMVC) of the dominant knee extensors (KE) 25 
and in vivo measures of VL muscle architecture, volume, activation and patella 26 
tendon moment arm were used to calculate VL physiological CSA (PCSA), fascicle 27 
force and specific force in both groups. Achondroplasia muscle volume was 53% 28 
smaller than controls (284 36 vs 604 102 cm3, P < 0.001). KE iMVC was 63% lower 29 
in Achondroplasia compared to controls (95 24 vs 256 47 Nm, P < 0.001). 30 
Activation and moment arm length were similar between groups (P > 0.05), but 31 
coactivation of Achondroplasia bicep femoris was 70% more than controls (43 20 vs 32 
13 5 %, P < 0.001). Achondroplasia had 58% less PCSA (43 10 vs 74.7 14 cm2, P < 33 
0.001), 29% lower fascicle force (702 235 vs 1704 303 N, P < 0.001) and 29% lower 34 
specific force than controls (17 6 vs 24 6 Ncm-2, P = 0.012). The smaller VL specific 35 
force in Achondroplasia may be attributed to infiltration of fat and connective tissue, 36 
rather than to any difference in myofilament function.  37 
 38 
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New and Note Worthy 43 
The novel observation of this study was the measurement of normalised force 44 
production in a group of individuals with disproportionate limb length to torso 45 
ratios.   46 
Introduction 47 
Achondroplasia is a condition characterised by disproportionate shorter limb length, 48 
to stature, compared to age matched average sized individuals (18, 21, 39, 45). The 49 
contribution of force from the muscle in proportionally smaller groups has been 50 
investigated with force production appearing to be proportional to muscle 51 
morphology, such as muscle volume and fascicle length (23, 37). With 52 
Achondroplasia displaying disproportionate limb length and reduced whole body and 53 
segmental muscle mass, the muscle architecture and force production capacity may 54 
in turn be altered, but such observations have not been identified in Achondroplasic 55 
populations. 56 
 57 
Muscle morphology, defined here as muscle size and architecture, is a primary 58 
determinant of muscle function and can account for some of the differences 59 
observed in proportionally smaller people (6, 23, 24, 37, 43, 44, 49). Primarily, the 60 
determinants of muscle force are: muscle shortening velocity, physiological cross 61 
sectional area (PCSA) of the muscle, fascicle length and muscle volume, respectively 62 
(38). Neural factors of the agonists and antagonists also contribute to force 63 
production as well as the biomechanical form of the joint (29, 32, 34). In numerous 64 
clinical conditions, such as the aging and cerebral palsy, the prevalence of weakness 65 
corresponds with functional impairments such as slower walking speeds and 66 
reduced performance of functional tasks (10, 22). In children with Achondroplasia 67 
isometric knee extension strength is less than age matched controls (51); there is 68 
however no comparison of force production capacity in adults with Achondroplasia, 69 
nor is there any measure of strength normalised for differences in muscle 70 
morphology or size. 71 
 72 
The measurement of specific force integrates the measurement of muscle size, 73 
architecture, neural capacity and moment arm, providing a normalised value of force 74 
production (11, 50). While there is some variability in specific force, the values are 75 
similar across different cohorts, muscles and species (9, 11, 30, 37, 50). While 76 
specific force is similar between muscle groups, such measurement in muscles of the 77 
leg, such as vastus lateralis (VL), allow an indication of gait ability and oxygen uptake 78 
(52). Furthermore, recently, a large cohort of adult males was measured in the VL, 79 
which can be used as a reference data set (50). To the Authors knowledge there has 80 
been no measurement of force production in Achondroplasic populations. 81 
Furthermore, to the authors knowledge, there appears to be no information on the 82 
adult Achondroplasic population in relation to force production, other than a general 83 
assumption that muscle mass is lower in this group compared to age matched 84 
average sized people, hereafter referred to as ‘controls’. The measurement of 85 
specific force therefore, will allow a comparison between Achondroplasia and 86 
controls that may differ in terms of neuromuscular, biomechanical and architectural 87 
properties of the myotendinous unit 88 
 89 
The aim of this study therefore is to assess specific force in adult males with 90 
Achondroplasia, and to identify the neural, morphological and biomechanical 91 
determinants of any difference in muscle force production between Achondroplasia 92 
and controls. 93 
 94 
Methods 95 
Participants 96 
After written consent, 28 participants volunteered to participate in the study. All 97 
were free from any lower limb injury six months prior six to data collection and self-98 
reported good health using a physical activity readiness questionnaire (mean (SD): 99 
10 adult male Achondroplasia, age: 22 (3) yrs, mass: 61.8 (8.5) kg, stature: 1.38 100 
(0.05) m, body fat: 29.3 (2.9) % and 18 adult males, age: 22 (2) yrs, mass: 78.3 (10.7) 101 
kg, stature: 1.79 (0.08) m, body fat: 22.4 (5.3) %). Ethical approval was attained by 102 
the local committee (Manchester Metropolitan University) and conformed to the 103 
declaration of Helsinki. Each participant attended one testing session at the 104 
laboratories of Manchester Metropolitan University where anthropometric, 105 
morphological and force measurements of the knee extensors (KE) were carried out. 106 
 107 
Whole Body Composition 108 
Participants were asked to fast for ~8 hrs before body composition assessment. A 109 
DEXA scanner (Hologic Discovery, Vertec Scientific Ltd, UK) was used to measure 110 
today body fat (%). A default whole body scan (EF 8.4 lSv) was selected for all trials; 111 
scans emitted dual energy (140/100 kVp) fan-beam x-rays and lasted for ~7 minutes 112 
with each participant being exposed to ~8.4 Sv (5). The scanning region was 195 cm 113 
x 65 cm with 1.3 cm line spacing and a 0.2 cm point resolution.  114 
 115 
Specific Force Calculation 116 
Strength measurements  117 
The torque derived from isometric maximal voluntary contraction (iMVC) of the 118 
dominant KE (Achondroplasia n = 9 right leg, control n = 16 right leg) were recorded 119 
using an isokinetic dynamometer (Cybex Norm, Cybex International Inc., NY, USA). 120 
Participants were seated upright with the dynamometer and chair positioned in 121 
accordance with the calibration guidelines given by the manufacturer so the lateral 122 
epicondyle was aligned with the dynamometer’s central axis of rotation. Particularly 123 
in the Achondroplasia group, the chair and dynamometer were adjusted to align the 124 
lateral epicondyle if needed; additional padding was placed behind the spine to help 125 
maintain a static knee angle throughout contractions. The participants’ dominant leg 126 
was secured with Velcro straps to the chair on the distal portion of the thigh and to 127 
the dynamometer around the lower portion of the tibia (~80% tibia length), 128 
according to participant comfort. All participants warmed up by performing six 129 
continuous submaximal concentric contractions (60˚·s-1) of the KE and knee flexors 130 
(KF). Participants then completed a randomised trial of KE iMVCs at 10° degree 131 
intervals, between 60° and 100°, to anatomical zero (where 180° was anatomical 132 
zero). Due to the chair being repositioned in the Achondroplasia group, joint angles 133 
were confirmed and recorded using a manual goniometer. Each participant received 134 
~120 seconds rest between each trial. Throughout iMVC trials, participants were 135 
verbally encouraged to exert as much force as possible. Visual feedback was also 136 
provided to all participants on a monitor. KE and KF iMVC values were recorded 137 
(2000 Hz) on a computer (Macintosh, iMac, Apple Computer, Cupertino, California) 138 
via an A/D converter using an acquisition system (AcqKnowledge, Biopac Systems, 139 
Santa Barbara, California). The angle that elicited peak KE iMVC was used for 140 
subsequent analysis. 141 
 142 
Agonist Activation 143 
Agonist activation of during KE iMVC production is assessed to observed maximal 144 
activation of the muscle and is done so while participants are positioned in the 145 
isokinetic dynamometer. Firstly, a counter weight was fixed to the dynamometer to 146 
minimise the compliance of the device. To measure agonist activation, two rubber 147 
stimulation pads (size ranging from 70x90 to 180x100 mm; Uni-Patch, MN, USA) 148 
were placed proximally and distally along the transverse plane of the dominant 149 
femur. While in a relaxed state, a percutaneous electrical doublet stimulus (DS7, 150 
Digitimer stimulator, Welwyn, Garden City, UK) was passed through the KE at 151 
increased increments (~50 mV) and regular intervals (~20 seconds) until a plateau of 152 
twitch torque was measured. This supramaximal doublet stimulus was applied to the 153 
participants KE (inter-stimulus gap 10 µs and pulse width 50 µs) during KE iMVC. 154 
Doublet stimulus has been shown to improve the signal-noise ratio in the 155 
assessment of central activation (4, 27). A second doublet was applied 156 
approximately 5 seconds after the first stimulus when the muscles were fully 157 
relaxed, termed the potentiated doublet. Agonist activation was calculated using the 158 
following equation: 159 
 160 
Activation (%) = 100 · (1 – ( 
t - iMVC
 T 
)) 
 161 
Where; t is the interpolated doublet amplitude of the twitch torque, iMVC is the 162 
isometric maximal voluntary contraction torque and T is the potentiated doublet 163 
amplitude (3).  164 
 165 
Measurement of Coactivation  166 
Co-activation of the KF was measured in all participants during a KE iMVC, and 167 
subsequent KF iMVC produced at the angle at which peak KE iMVC was measured. 168 
In order to determine coactivation of the KF, surface EMG was recorded over the 169 
biceps femoris (BF) as it is the largest of the KF group, and is representative of the KF 170 
group as a whole (26). Furthermore, surface EMG was deemed adequate despite the 171 
adiposity levels in Achondroplasia (17, 21, 42), as no differences in EMG readings are 172 
observed between groups of differing adiposity (8). Boundaries of the BF were 173 
determined using ultrasonography (Technos MXP Biosound Esaote) to ensure 174 
consistent placement of EMG electrodes over the KF. When established two pre-175 
gelled, unipolar, 10mm, Ag-AgCl percutaneous electromyography (EMG) electrodes 176 
(Ambu Neuroline 720, Baltorpbakken, Denmark) were placed distally at ~1/3 of 177 
muscle length, to avoid the motor unit of the BF, and ~2mm apart along the mid-178 
sagittal plane of the muscle (NORAXON, Arizona, USA). A third electrode was placed 179 
on the lateral epicondyle of the same femur as a reference. Prior to the placement of 180 
the electrodes, areas of the skin were shaved, then cleaned using an alcoholic wipe 181 
to minimise skin impedance and hence improve the EMG signal. Raw EMG data were 182 
recorded at 2000 Hz, with a high and low band-pass filter set at 10 and 500 Hz 183 
respectively, and a notch set at 50 Hz. The integral of the root mean square was 184 
recorded 0.5 seconds either side of the KE and KF iMVC to quantify the level of KF 185 
muscle coactivation. Based on a linear relationship occurring between torque and 186 
EMG activity (32), KF torque during KE iMVC was derived by converting the 187 
percentage activation of KF EMG during KE iMVC to KF EMG during KF iMVC.  188 
 189 
 KFτ = (
((KE ÷ KF) · 100) 
100
) · KF iMVC 
 190 
Where KF is the KF torque during KE (Nm), KE is the agonist EMG (mV) recorded of 191 
the KE during KE iMVC, KF is the antagonist EMG (mV) recorded of the KE during KE 192 
iMVC and KF iMVC is the torque (Nm) observed during KF iMVC.  193 
 194 
The measurement of agonist and antagonist muscle activation are required for the 195 
accurate quantification of net KE iMVC production, both of which are used in the 196 
calculation of specific force (30, 50). Therefore, net KE iMVC was given as the sum 197 
of KE iMVC and KF while a ratio of KF iMVC and KE iMVC was calculated to 198 
describe a balance of quadriceps to hamstring strength. 199 
 200 
Measurement of Muscle volume 201 
To measure VL ACSA, B-mode ultrasonography (Technos MXP Biosound Esaote) was 202 
used to obtain a 50 % muscle length transverse plane image of the VL (48). The 203 
origin and insertion of the dominant VL were marked, along with regular intervals of 204 
the medial and lateral edges. Muscle length (cm) was determined by the distance 205 
between the origin and insertion points with the 50 % percentile marked on the skin. 206 
A wire mesh was secured to the skin using non-allergic tape along the transverse 207 
plane. The wires were separated ~3 cm apart and ran sagittal to the muscle to act as 208 
echo absorbing markers that projected a shadow on the ultrasound image to act as 209 
reference points for analysis (48). The 5cm 7.5 MHz linear array probe was placed 210 
transversely to the VL with ultrasound transmission gel across the skin. While the 211 
probe moved from the medial to the lateral border of the VL, an audio video 212 
interleave (AVI) recording with a sampling frequency of 25 Hz (Adobe Premiere 213 
Elements version 10, Adobe Systems) was taken. The field of view was set so that 214 
anatomical references (femur and aponeurosis between VL and vastus intermedius) 215 
were visible at all times. Measurements were taken while the participant was supine 216 
and at rest. Individual images (between 5-9), with at least two wire references, were 217 
extracted from the recording and used to re-construct the muscle by overlapping the 218 
wire and aforementioned anatomical references, on photo editing software (Gimp, 219 
Version 2.8.8, GNU Image Manipulation Program). Digitising software (NIH Image J, 220 
Version 1.44o, National Institutes of Health, Bethesda, Maryland) was used to 221 
measure the ACSA of the VL. The volume of the VL was calculated using previously 222 
reported constants of MRI regression (35), where:  223 
  224 
VL Volume = (
-2.9244
4
 + 
0.74
3
 + 
2.2178
2
 + 0.0244) · VL length · 50% ACSA 
 225 
Muscle architecture  226 
In vivo muscle architecture of the VL was conducted using B-mode ultrasonography 227 
(Technos MXP Biosound Esaote) during KE iMVC to observe fascicle length (cm) and 228 
pennation angle (θ). The 5cm, 7.5 MHz linear array probe was held on the mid-229 
sagittal plane on a previously established mid-point of the VL; measured equidistant 230 
from the origin-insertion and medial-lateral muscular borders. With water-soluble 231 
transmission gel the probe was held against, and at a perpendicular angle to, the 232 
skin with minimal pressure. The depth of view was set to ensure a number of 233 
fasciculi insertion points and deep aponeurosis were in view (30). Ultrasound 234 
imaging and torque production were synchronised using an external square wave 235 
voltage trigger enabling the accurate attainment of iMVC-to-ultrasound. Image 236 
recordings were AVI format at a sample frequency of 25 Hz; single images were 237 
selected using capture software (Adobe Premiere Elements version 10, Adobe 238 
Systems). Images of the VL at rest and iMVC were analysed using digitising software 239 
(NIH ImageJ, Version 1.44o, National Institutes of Health, Bethesda, Maryland) 240 
whereby fascicle length was determined as the length between the superficial and 241 
deep aponeuroses (38) and pennation angle was defined as the insertion angle of 242 
the fascicle into the deep aponeurosis (30). With the VL being one of the larger 243 
muscles in the body, invariably the dimensions of the probe was not large enough to 244 
capture a full fascicle, for these cases linear extrapolation was used to determine 245 
fascicle length as little error (2-7%) is observed at the midpoint of the muscle (14, 246 
15), again using digitising software described above. 247 
 248 
Physiological Cross Sectional Area 249 
The PCSA (cm2) was estimated as the ratio of VL muscle volume to fascicle length 250 
(30), assuming the model used to calculate muscle volume is cylindrical and that the 251 
muscle fibres are constant length (48). 252 
 253 
Moment arm length 254 
A dual-energy X-ray absorptiometry (DEXA) scanning (Hologic Discovery, Vertec 255 
Scientific Ltd, UK), in single energy mode (100 kVp), was used to obtain moment arm 256 
length of the patella tendon (PTMA) (12). Participants were asked to lie on their side 257 
in a relaxed state. The dominant knee was positioned at the angle acquired from 258 
optimal peak force production using a manual goniometer. A single array sagittal 259 
plane scan was taken of the knee using a 22.3 x 13.7 cm field of view. Obtained scans 260 
were exported to and analysed on a Dicom viewer (OsiriZ 5.0.2, Pixmeo Sarl, Geneva, 261 
Switzerland). Moment arm length (m) was determined as the perpendicular distance 262 
between the estimated tibiofemoral contact point and the posterior aspect of the 263 
patella tendon (57). 264 
 265 
Fascicle Force and Specific Force  266 
To estimate VL fascicle force and in turn specific force the following steps were used: 267 
Patella tendon force (N) was calculated using the following equation (41): 268 
 269 
FPT = 
Net KE iMVC 
MA
 
 270 
Where FPT is the force at the patella tendon (N) during KE iMVC, net KE iMVC is 271 
calculated above, and MA is the length of the moment arm (m). 272 
 273 
Previously reported data shows the relative contribution of the VL to the patella 274 
tendon to be around 22% (38). This calculation was then used to calculate VL fascicle 275 
force by expressing the VL fascicle force as a ratio of the VL contribution to the 276 
cosine of the pennation angle (radians) at KE iMVC. 277 
 278 
Fascicle Force =
VLcon
cosθ
 
 279 
Where VLCon is the VL contribution (N) and cosθ is the cosine of pennation at iMVC 280 
(radians). 281 
 282 
Specific force was represented as the ratio between VL fascicle force and VL PCSA.  283 
 284 
Statistical Analysis 285 
All data was collated onto a personal computer (Macintosh, MacBook Pro, Apple 286 
Computer, Cupertino, California) and analysed using SPSS (v22.0, IBM). Data was 287 
assumed parametric following Shapiro-Wilk and Levene’s tests. Independent t-tests 288 
were carried out on most measured variables. In addition, Pearson’s correlations 289 
were performed between related dependent variables. For variables that violated 290 
parametric assumptions, a Levene’s adjusted P value or a Mann-Whitney U (denoted 291 
by * and †, respectively, in Tables 1 and 2) was performed. Study power was 292 
assessed using G*Power and was found to be above 0.8 and alpha was set at ≤ 0.05. 293 
All results are reported as means (SD). 294 
 295 
Results 296 
Achondroplasia were 23% smaller in stature (P < 0.001) and 19% lighter in body mass 297 
(P < 0.001). There was no difference in age between groups (P = 0.487). 298 
 299 
KE and KF iMVC 300 
Adult males with Achondroplasia produced 63% less KE iMVC than controls (Table 301 
1). KF iMVC was also significantly different (Table 1), again with Achondroplasia 302 
producing 82% less KE iMVC than controls. When expressed as a ratio between 303 
absolute KE iMVC and KF iMVC, Achondroplasia produced 49% more iMVC from 304 
the KE compared to KF than controls (Table 2). 305 
 306 
Activation and Coactivation 307 
There was no difference in maximal activation between Achondroplasia and control 308 
participants, however Achondroplasia had a 70% greater coactivation of the BF 309 
during KE iMVC compared to controls (Table 1). 310 
 311 
Net KE iMVC 312 
Paired samples t-test revealed that both groups significantly increased KE iMVC 313 
when corrected for BF coactivation, with Achondroplasia increasing by 7% and 314 
controls by 5% respectively (Table 1). The net KE iMVC produced by the VL was 63% 315 
less in Achondroplasia compared to controls (Table 1). There was no significant 316 
correlation between body fat percentage and net KE iMVC in Achondroplasia (r = 317 
0.110, P = 0.763) or controls (r = 0.411, P = 0.090). 318 
 319 
Morphology and Architecture 320 
Achondroplasia had 41% smaller VL length than control (Table 1). VL morphology 321 
differed between groups with Achondroplasia having a 20% smaller ACSA than 322 
control (Table 1, Figure 2) and in turn a 53% smaller muscle volume than controls 323 
(Table 1). Achondroplasia exhibited a 17% greater pennation angle (Table 1) but 17% 324 
smaller fascicle length (Table 1) during KE iMVC. PCSA was found to be 42% smaller 325 
in Achondroplasia than controls (Table 1). Correlations revealed no significant 326 
relationship between VL muscle volume and net KE iMVC production in 327 
Achondroplasia (R2 = 0.056, P = 0.508, Figure 1), whereas for the same variables in 328 
controls, a significant relationship did exist (R2 = 0.286, P = 0.022, Figure 1). Despite 329 
the diverging regression lines, a Z-transformation showed the slopes were similar (P 330 
= 0.442). 331 
 332 
Presenting KE iMVC as a ratio to ACSA, Achondroplasia produce 53% less force per 333 
unit area compared to controls (Table 2). When net KE iMVC is expressed as a ratio 334 
with total body mass, Achondroplasia again display a 43% reduction to controls 335 
(Table 2). Achondroplasia displayed a 67%, reduction in net KE iMVC when 336 
presented as a ratio to LBM (Table 2). There was no relationship between ACSA and 337 
PCSA (R2 = 0.016, P > 0.05) for Achondroplasia, whereas a significant relationship for 338 
the same variables was observed for controls (R2 = 0.254, P = 0.032). 339 
 340 
Force Measurements 341 
The length of the PTMA were similar between Achondroplasia and controls (Table 1). 342 
All force measurements were statistically lower in Achondroplasia compared to 343 
controls with patella tendon force, fascicle force and specific force being 60, 59 and 344 
29% lower, respectively (Table 1).  345 
 346 
Discussion 347 
Here we aimed to assess the in vivo muscle morphology, KE iMVC production and 348 
specific force of the VL in adults with Achondroplasia and age and gender-matched 349 
healthy adults. The main findings were 1) net KE iMVC, VL ACSA, volume and PCSA 350 
were smaller in Achondroplasia than controls, 2) differences in net KE iMVC were 351 
not accounted for by the differences in muscle size 3) KF coactivation was higher in 352 
Achondroplasia than controls, 4) when morphological, architectural, neurological 353 
and biomechanical differences were accounted for, a 29% smaller specific force was 354 
observed in Achondroplasia.  355 
 356 
A large portion of neuromuscular function research describes the relationship 357 
between muscle size and force production, suggesting that muscle size is the 358 
predetermining factor for muscle strength (7, 33, 50, 54). Groups of shorter statures 359 
consistently present with smaller muscle size and lower MVC strength than their 360 
taller counterparts (6, 23, 37, 43, 49); when iMVC is normalised to muscle size, 361 
differences between control and short stature groups are nullified (6, 23, 49).  The 362 
data from the present study is partially consistent with these previous findings. 363 
Achondroplasia were 82% weaker than controls in terms of KE iMVC, however this 364 
was not entirely accounted for by ACSA which was only 20% smaller. It is likely 365 
therefore that architectural and neurological factors contribute to weakness in 366 
Achondroplasia. It should be noted however that despite accounting for these 367 
factors, a deficit in Achondroplasic specific force remains, which could be 368 
subsequently attributed to physiological factors between groups or methodological 369 
measures of specific force, as discussed below. 370 
 371 
Muscle Morphology in Achondroplasia 372 
The extent of group differences in muscle size between Achondroplasia and controls 373 
was not consistent for each variable. For example, a 20% smaller VL ACSA in 374 
Achondroplasia underestimated the difference in PCSA which was 42% smaller than 375 
controls. This was due to the smaller muscle length and hence smaller VL volume in 376 
Achondroplasia compared to controls. ACSA must therefore be considered an 377 
inaccurate method of assessing contractile area between groups of heterogeneous 378 
muscle length such as presented here.  379 
 380 
Although PCSA is the closest approximation to sarcomeres in parallel and therefore 381 
contractile area (28), it is possible that PCSA may be overestimated in the 382 
Achondroplasic group. The over estimation of PCSA in Achondroplasia is likely due to 383 
the differences in architectural properties at iMVC between groups. In controls, 384 
increased tendon compliance (i.e. more strain when under a relative force) alters 385 
muscle architecture at iMVC, with increased pennation angle, fibre shortening and a 386 
leftward shift in the length tension relationship observed (30, 46, 47). Here, only 387 
increased pennation angle between groups was observed as resting fibre length not 388 
measured. Assuming the Achondroplasic patella tendon is more compliant than 389 
controls, given the observations made here, Achondroplasic fibre length is likely to 390 
be shorter at iMVC than it would be were patella tendon compliance the same 391 
between groups. PCSA is therefore overestimated as PCSA = ACSA/fibre length. 392 
Given that PCSA is the denominator when calculating specific force, a large PCSA 393 
(with the same fascicle force) equates to a lower specific force. For example, in the 394 
present study, Achondroplasia fibre length was 17% shorter and were 17% more 395 
pennate at iMVC than controls. Were the fibre angle to remain the same between 396 
groups at KE iMVC, fibre length of Achondroplasia would be 9% longer than the 397 
presented values and result in a 47% smaller PCSA compared to controls, 5% more 398 
than the measured values. This consequently leads to a 15% smaller Achondroplasic 399 
specific force compared to controls. The differences in muscle architecture at iMVC 400 
between groups therefore appears to contribute to the difference in specific force 401 
and could be partly due to a more compliant Achondroplasia patella tendon. 402 
However, there appears to be no measure of Achondroplasic tendon compliance 403 
within the literature to confirm this. Furthermore, this theory may only explain some 404 
of the 23% difference in specific force between groups.  405 
 406 
Specific Force 407 
Specific force provides an accurate representation of the in vivo contractile 408 
properties of the whole muscle and has been used to described the force 409 
characteristics of numerous different cohorts and muscle groups (9, 11, 15, 30, 36-410 
38, 43, 50). Recently it has been shown that inter-individual variability in the 411 
measurements of specific force eludes to the fact that population variance in specific 412 
force may be due to a lower fibre specific force (i.e. myofilament differences), or an 413 
overestimation of muscle area through the inclusion of non-contractile material in 414 
the measurement of muscle mass (50). Several research groups have investigated 415 
specific force production at the myofilament level to identify intramuscular 416 
differences (55, 56, 58). In the present study, specific force was measured at the 417 
fascicle level, with no apparent measure of force production made at the 418 
myofilament level in Achondroplasia. It could be suggested though, that as 419 
Achondroplasia is determined by a collagenous defect during development (19, 20), 420 
the protein structures at the myofilament level may be different to controls, which 421 
may contribute to the presented lower Achondroplasic specific force. 422 
 423 
It is possible that the presentation of a lower specific force could be due, in part, to 424 
an overestimation of muscle size owing to the use of ultrasound to measure ACSA. 425 
Ultrasound, as with MRI, requires the measurement of the area encapsulated by 426 
aponeuroses to determine ACSA. The area within these limits includes muscle, 427 
connective tissue and fat infiltration. Previous reports (16, 17, 42) and here, show 428 
that Achondroplasic individuals have increased body fat percentage. The fibroblast 429 
mutation that causes Achondroplasia may also play some part in connective tissue 430 
distribution within the muscle, although this is at present unreported. Therefore, the 431 
measured Achondroplasic ACSA may reflect a “pseudo-hypertrophy” due to the 432 
probable increase of intramuscular fat infiltration, as observed in people with 433 
increased body fat (53). This pseudo-hypertrophy would increase muscle volume and 434 
PCSA measurement, with no change in contractile mass and in turn reduce the 435 
calculation of Achondroplasic specific force; it is important to note here that this 436 
methodological limitation is not only present in Achondroplasia. Regardless of these 437 
methodological discrepancies, when scaling strength and muscle size, a lower 438 
specific force persists in the present Achondroplasia participants which could be 439 
attributed to either an infiltration of non-contractile material, differences in single 440 
fibre properties or differences in tendon properties. 441 
 442 
Coactivation and Moment Arm Length 443 
In this study, the use of DEXA to measure PTMA led to two important observations of 444 
the Achondroplasic knee. Firstly, there appears to be a lower joint congruency 445 
between femur and tibia in the Achondroplasic knee (Figure 3), agreeing with 446 
observations by Aykol et al. (1). The apparent reduced tibiofemoral joint congruency 447 
in Achondroplasia would likely reduce tibiofemoral joint stability. In clinical, injured 448 
and juvenile populations, where joint congruency is reduced, increased coactivation 449 
of the BF is observed during KE (13, 25, 26). In the present study, Achondroplasia had 450 
a 70% increased coactivation of the BF during KE iMVC compared to controls. 451 
Therefore, the increased coactivation of Achondroplasic BF during KE iMVC is likely 452 
due to the reduced tibiofemoral joint congruency. Furthermore, the increased 453 
coactivation of the Achondroplasic BF may act as an injury prevention mechanism. In 454 
this case, Achondroplasic hamstrings are activating during KE to reduce the anterior 455 
movement of the tibia in relation to the femur. This would protect ligamentous 456 
structures in the knee, such as the anterior cruciate ligament. It is probable that this 457 
mechanism exists in other Achondroplasic muscle groups and joints as well as the 458 
knee. The increased coactivation of hamstrings, and other muscles, may also 459 
influence activities of daily living, such as walking economy. There is however, a lack 460 
of comparative data expressing the activation profiles of Achondroplasic muscle 461 
during contraction to expand on the theories presented. Therefore, the suggestions 462 
made from the current findings warrant further work. 463 
 464 
The second observation from DEXA scanning of the Achondroplasic knee was that 465 
absolute PTMA between groups was the same, meaning that Achondroplasia have a 466 
longer PTMA relative to the femur (here measured as VL length). This finding is 467 
different to other shorter statured groups who show a proportionally smaller 468 
moment arms compared to taller statured individuals (37). The relatively larger PTMA 469 
in Achondroplasia is likely to aid KE torque production, despite the 63% lower net KE 470 
iMVC compared to controls. For example, were the PTMA of the current 471 
Achondroplasic population to be proportionally smaller to their femur length (i.e. 472 
37% shorter), Achondroplasia would have produced 76% less net KE iMVC than 473 
controls. Whilst PTMA appears to aid Achondroplasic torque production, PTMA 474 
changes during KE (2, 31, 32) which leads to differences in force production (57). In 475 
the present study, we measured PTMA at rest and did not account for changes of 476 
PTMA during contraction. We assumed that the changes in PTMA during KE iMVC 477 
would be similar between groups as it is unreported if Achondroplasic PTMA changes 478 
in a similar fashion to control’s PTMA during KE. Any change in Achondroplasic PTMA 479 
during contraction may further aid or hinder Achondroplasic torque production, but 480 
this is yet to be observed. The presented data from this study appears to be the only 481 
data that accounts for Achondroplasic moment arm during contraction in any joint. 482 
 483 
Clinical Implications 484 
The present observations of a lower specific force, higher body fat, shorter stature 485 
and lower muscle volume in Achondroplasia, could contribute to those with 486 
Achondroplasia requiring a greater relative force production to complete activities of 487 
daily living compared to controls, such as walking. During walking, the lower muscle 488 
volume and higher body mass of Achondroplasic individuals would likely increase the 489 
required force production per step to maintain locomotion. This increased force 490 
production may in turn increase Achondroplasic walking economy. Furthermore, the 491 
decrease in Achondroplasic KE and KF iMVC, higher hamstring coactivation and 492 
lower specific force would suggest Achondroplasia may be at greater risk of falls and 493 
reduced postural stability compared to controls, as observed in control groups (40). 494 
Therefore, addressing interventions which aim to increase the absolute force 495 
production of Achondroplasic muscle would likely increase their quality of life by 496 
aiding walking economy, reducing the risk of falling and reducing injury risk. 497 
 498 
Conclusion  499 
This is the first study, to the authors knowledge, that has systematically accounted 500 
for various physiological and biomechanical modulators of force production in 501 
muscles of Achondroplasia. The main finding is that Achondroplasia produce 23% 502 
less specific force than controls. These results may only explain the variance in 503 
muscle morphology as further work into methodological, and myofilament 504 
differences within Achondroplasic specific force is needed to increase the validity of 505 
these data.  506 
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Figure and table titles 680 
 681 
Figure 1: Scatter plot showing the relationship between VL muscle volume (cm3) and 682 
torque production (N·m) for Achondroplasia (open) and controls (closed). Trend lines 683 
including R2 are also given for each group respectively. 684 
 685 
Figure 2:  50% ACSA of Achondroplasia (A) and a healthy adult (B). VL: Vastus 686 
Lateralis; VI: Vastus Intermedius; F: Femur. 687 
 688 
Figure 3: Sagittal knee scans of 1 Achondroplasia (A) and 1 control (B) showing the 689 
reduced femoral contact point with the tibia in Achondroplasia. 690 
 691 
Table 1: Morphological and functional characteristics of the vastus lateralis in 692 
controls and Achondroplasic adults. Values presented as mean (SD). 693 
 694 
Table 2: Morphological and functional characteristics of the vastus lateralis 695 
normalised anatomical structures in controls and Achondroplasic adults. Values 696 
presented as mean (SD). 697 



   Control Achondroplasia P value 
iMVC KE (N·m)  256 (47) 95 (24) < 0.001 
iMVC KF (N·m) * 105 (19) 19 (7) < 0.01 
Activation (%) * 92.0 (5.9) 83.9 (13.9) 0.105 
Coactivation (%) * 12.6 (5.3) 42.6 (20) 0.001 
Net iMVC (N·m) † 287 (49) 106 (26) < 0.001 
Volume (cm3) * 604 (102) 284 (36) < 0.001 
Fascicle Length (cm) * 8.2 (1.5) 6.8 (1.5) 0.027 
ACSA (cm2) * 27.7 (4.4) 22.2 (2.6) < 0.001 
Pennation Angle (°) † 17.4 (2.4) 20.9 (4.6) 0.027 
Muscle Thickness (cm) 28.4 (7.6) 20.6 (8.3) 0.550 
PCSA (cm2) 74.7 (13.7) 43.2 (9.9) < 0.001 
Moment Arm (m) † 0.040 (0.002) 0.037 (0.005) 0.309 
Patella Tendon Force (N) 7296 (1319) 2930 (974) < 0.001 
VL Fascicle Force (N) 1704 (303) 702 (235) < 0.001 
Specific Force (N·cm-2) † 23.6 (6.4) 16.7 (6.0) 0.014 
iMVC, isometric maximal voluntary contraction torque; ACSA, anatomical cross-
sectional area; PCSA, physiological cross-sectional area. * adjusted P value 
following Levene’s; † Mann Whitney-U.  
 
 
 
  Control Achondroplasia P Value 
iMVC KE:KF (%) 41.1 (9.2) 20.2 (6.7) < 0.001 
VL Length:Stature (%) † 18.8 (0.8) 14.3 (0.7) < 0.001 
TBM:Volume (kg·cm-3) 7.76 (1.17) 4.65 (0.69) < 0.001 
Net iMVC:ASCA (N·m·cm-2) 2.14 (0.37) 2.81 (0.73) 0.003 
Net iMVC:TBM (N·m·kg-1) 3.72 (0.71) 1.71 (0.28) < 0.001 
Net iMVC:LBM (N·m·kg-1) † 4.99 (0.78) 2.54 (0.43) < 0.001 
Net iMVC:Volume (N·m·cm-3) 0.48 (0.08) 0.38 (0.10) 0.006 
PT Moment arm:VL Length (cm) † 11.78 (0.96) 19.07 (3.25) < 0.001 
Net iMVC:PSCA (N·m·cm-2) 3.96 (0.99) 2.55 (0.80) 0.001 
VL, vastus lateralis; TBM, Total Body Mass, iMVC, isometric maximal voluntary 
contraction torque; ACSA, anatomical cross-sectional area; PCSA, physiological cross-
sectional area; PT, patella tendon. † Mann Whitney-U.  
 
